NCT07094477View on ClinicalTrials.gov

Study of Targeted CD22/CD19 CAR-T Therapy for First-line Consolidation of B-cell Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions

Lymphoma

Interventions

DRUG

CD22/CD19 CAR-T cell immunotherapy

targeted CD22/CD19 CAR-T cell immunotherapy

Trial Locations (1)

100853

Chinese PLA General Hospital, Beijing

All Listed Sponsors

lead

Daihong Liu

OTHER